US 12377058 B1Patent grantUnited States

Substituted Compounds for Cancer Cell Screening

Official patent title

Method for inhibiting proliferation of cancer cells

Arabic title: طريقة لتثبيط تكاثر الخلايا السرطانية

Invention

Problem

Cancer treatment remains limited by incomplete response, toxicity, resistance, and effects on patient well-being, creating a need to investigate compounds that inhibit proliferation or induce apoptosis in cancer-cell models.

Why it matters

A chemically defined cytotoxic scaffold could provide a lead for anticancer research, but cell-culture activity does not demonstrate safety, selectivity, animal efficacy, dosing, or clinical benefit.

Approach

The patent contacts cancer cells with a substituted anticancer compound of Formula (I), reports apoptosis and proliferation endpoints, describes Formula (II), and provides a synthesis from phenol and benzaldehyde compounds.

Who may benefit

Potential beneficiaries include oncology drug-discovery groups, medicinal-chemistry laboratories, cancer-cell biology researchers, translational research centers, and pharmaceutical developers evaluating early-stage cytotoxic compounds.

Potential value

The disclosure connects a defined substitutable compound class with reported cell-line IC50 ranges, a preparation route, several cancer-cell models, and an optional doxorubicin combination for further research.

Background

Cancer involves uncontrolled growth and spread of abnormal cells. Apoptosis pathways, including caspases and Bcl-2-family regulation, are common targets for therapeutic research, while inflammatory markers may help characterize disease biology or response. Existing treatments can be limited by toxicity, resistance, cost, or effects on general well-being. The patent therefore investigates a substituted organic compound for cytotoxicity and apoptosis in cancer-cell models. These laboratory endpoints are preliminary and cannot establish treatment efficacy or safety in animals or people.

Technology overview

Formula (I) permits R1–R8 to be hydrogen, halogen, or optionally substituted alkyl groups. The patent reports an IC50 range of 2–10 μg/ml for proliferation inhibition and apoptosis and lists A549, PC3, FaDu, triple-MDA-MB-468, and HeLa models with model-specific ranges. A preparation route mixes a phenol compound, benzaldehyde compound, and inorganic base in solvent and heats at 120–160 °C. One embodiment evaluates Formula (II) in the presence of doxorubicin.

Potential applications

Potential lead-compound studies in cancer-cell proliferation assays.
Potential apoptosis-mechanism research in listed cell models.
Potential medicinal-chemistry optimization of Formula (I) substituents.
Potential in-vitro combination studies with doxorubicin.

Evidence-supported advantages

Defines a substitutable anticancer-compound scaffold.
Reports IC50 ranges for several named cell models.
Includes a specified chemical preparation route.
Provides an optional doxorubicin combination embodiment.

Development stage

Patent publication describing compound synthesis and in-vitro cell assays; independent validation, animal or clinical efficacy, safety, and commercialization were not established.

Commercial opportunity

The compound class may support early-stage oncology discovery or research licensing. Required work includes identity and purity confirmation, reproducible potency, normal-cell selectivity, mechanism studies, pharmacokinetics, formulation, metabolism, genotoxicity and toxicity, animal efficacy, dose and route development, combination safety, manufacturing controls, and ultimately regulated clinical studies before any therapeutic claim.

Patent classifications

WIPO IPC

A61K31/09Preparations for medical, dental or toiletry purposes
A61P35/00Specific therapeutic activity of chemical compounds or medicinal preparations

CPC

A61K31/09Preparations for medical, dental or toiletry purposes
A61P35/00Specific therapeutic activity of chemical compounds or medicinal preparations
G01N33/5758Investigating or analysing materials by determining their chemical or physical properties
G01N2800/52Investigating or analysing materials by determining their chemical or physical properties

Inventors

First inventorTarek Ahmed Yousef
InventorSaad Shaaban
InventorHussein Ba-Ghazal
InventorMarwa Sharaky
InventorAhmed A. Al-Karmalawy

Keywords

cancer cells
proliferation inhibition
apoptosis
cytotoxic compound
IC50
Formula I
doxorubicin
medicinal chemistry

Patent document and drawings

The patent publication is mapped to this record. Patent drawings remain within that publication; no separately cleared public media package has been supplied.